325 related articles for article (PubMed ID: 26298797)
21. Results of a phase II randomized, double-blind, placebo-controlled trial of Polyphenon E in women with persistent high-risk HPV infection and low-grade cervical intraepithelial neoplasia.
Garcia FA; Cornelison T; Nuño T; Greenspan DL; Byron JW; Hsu CH; Alberts DS; Chow HH
Gynecol Oncol; 2014 Feb; 132(2):377-82. PubMed ID: 24388920
[TBL] [Abstract][Full Text] [Related]
22. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer.
Crew KD; Brown P; Greenlee H; Bevers TB; Arun B; Hudis C; McArthur HL; Chang J; Rimawi M; Vornik L; Cornelison TL; Wang A; Hibshoosh H; Ahmed A; Terry MB; Santella RM; Lippman SM; Hershman DL
Cancer Prev Res (Phila); 2012 Sep; 5(9):1144-54. PubMed ID: 22827973
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
[TBL] [Abstract][Full Text] [Related]
24. Metabolic response to epigallocatechin-3-gallate in relapsing-remitting multiple sclerosis: a randomized clinical trial.
Mähler A; Steiniger J; Bock M; Klug L; Parreidt N; Lorenz M; Zimmermann BF; Krannich A; Paul F; Boschmann M
Am J Clin Nutr; 2015 Mar; 101(3):487-95. PubMed ID: 25733633
[TBL] [Abstract][Full Text] [Related]
25. Lung cancer inhibitory effect of epigallocatechin-3-gallate is dependent on its presence in a complex mixture (polyphenon E).
Fu H; He J; Mei F; Zhang Q; Hara Y; Ryota S; Lubet RA; Chen R; Chen DR; You M
Cancer Prev Res (Phila); 2009 Jun; 2(6):531-7. PubMed ID: 19470785
[TBL] [Abstract][Full Text] [Related]
26. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
27. Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus.
Joe AK; Schnoll-Sussman F; Bresalier RS; Abrams JA; Hibshoosh H; Cheung K; Friedman RA; Yang CS; Milne GL; Liu DD; Lee JJ; Abdul K; Bigg M; Foreman J; Su T; Wang X; Ahmed A; Neugut AI; Akpa E; Lippman SM; Perloff M; Brown PH; Lightdale CJ
Cancer Prev Res (Phila); 2015 Dec; 8(12):1131-7. PubMed ID: 26471236
[TBL] [Abstract][Full Text] [Related]
28. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis.
Khan O; Shen Y; Caon C; Bao F; Ching W; Reznar M; Buccheister A; Hu J; Latif Z; Tselis A; Lisak R
Mult Scler; 2005 Dec; 11(6):646-51. PubMed ID: 16320723
[TBL] [Abstract][Full Text] [Related]
29. A randomized, double-blind, four-arm parallel-group, placebo-controlled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts.
Gross G; Meyer KG; Pres H; Thielert C; Tawfik H; Mescheder A
J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1404-12. PubMed ID: 17958849
[TBL] [Abstract][Full Text] [Related]
30. The association between retinal nerve fibre layer thickness and N-acetyl aspartate levels in multiple sclerosis brain normal-appearing white matter: a longitudinal study using magnetic resonance spectroscopy and optical coherence tomography.
Pardini M; Botzkowski D; Müller S; Vehoff J; Kuhle J; Ruberte E; Würfel J; Gass A; Valmaggia C; Tettenborn B; Putzki N; Yaldizli Ö
Eur J Neurol; 2016 Dec; 23(12):1769-1774. PubMed ID: 27591406
[TBL] [Abstract][Full Text] [Related]
31. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
[TBL] [Abstract][Full Text] [Related]
32. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.
NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators
Lancet Neurol; 2015 Aug; 14(8):795-803. PubMed ID: 26116315
[TBL] [Abstract][Full Text] [Related]
33. Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial.
Stockfleth E; Beti H; Orasan R; Grigorian F; Mescheder A; Tawfik H; Thielert C
Br J Dermatol; 2008 Jun; 158(6):1329-38. PubMed ID: 18363746
[TBL] [Abstract][Full Text] [Related]
34. Green tea polyphenol (-)-epigallocatechin-3-gallate triggered hepatotoxicity in mice: responses of major antioxidant enzymes and the Nrf2 rescue pathway.
Wang D; Wang Y; Wan X; Yang CS; Zhang J
Toxicol Appl Pharmacol; 2015 Feb; 283(1):65-74. PubMed ID: 25585349
[TBL] [Abstract][Full Text] [Related]
35. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
Miller AE; Wolinsky JS; Kappos L; Comi G; Freedman MS; Olsson TP; Bauer D; Benamor M; Truffinet P; O'Connor PW;
Lancet Neurol; 2014 Oct; 13(10):977-86. PubMed ID: 25192851
[TBL] [Abstract][Full Text] [Related]
36. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
[TBL] [Abstract][Full Text] [Related]
37. Effect of 2-month controlled green tea intervention on lipoprotein cholesterol, glucose, and hormone levels in healthy postmenopausal women.
Wu AH; Spicer D; Stanczyk FZ; Tseng CC; Yang CS; Pike MC
Cancer Prev Res (Phila); 2012 Mar; 5(3):393-402. PubMed ID: 22246619
[TBL] [Abstract][Full Text] [Related]
38. United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts.
Oketch-Rabah HA; Roe AL; Rider CV; Bonkovsky HL; Giancaspro GI; Navarro V; Paine MF; Betz JM; Marles RJ; Casper S; Gurley B; Jordan SA; He K; Kapoor MP; Rao TP; Sherker AH; Fontana RJ; Rossi S; Vuppalanchi R; Seeff LB; Stolz A; Ahmad J; Koh C; Serrano J; Low Dog T; Ko R
Toxicol Rep; 2020; 7():386-402. PubMed ID: 32140423
[TBL] [Abstract][Full Text] [Related]
39. Effects of encapsulated green tea and Guarana extracts containing a mixture of epigallocatechin-3-gallate and caffeine on 24 h energy expenditure and fat oxidation in men.
Bérubé-Parent S; Pelletier C; Doré J; Tremblay A
Br J Nutr; 2005 Sep; 94(3):432-6. PubMed ID: 16176615
[TBL] [Abstract][Full Text] [Related]
40. ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial.
Torkildsen O; Wergeland S; Bakke S; Beiske AG; Bjerve KS; Hovdal H; Midgard R; Lilleås F; Pedersen T; Bjørnarå B; Dalene F; Kleveland G; Schepel J; Olsen IC; Myhr KM
Arch Neurol; 2012 Aug; 69(8):1044-51. PubMed ID: 22507886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
